Combs Stephanie E, Thilmann Christoph, Huber Peter E, Hoess Angelika, Debus Jürgen, Schulz-Ertner Daniela
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany.
Cancer. 2007 Jun 1;109(11):2308-14. doi: 10.1002/cncr.22703.
The long-term outcome in patients with craniopharyngiomas treated with fractionated stereotactic radiotherapy (FSRT) was evaluated.
A total of 40 patients with craniopharyngiomas were treated between May 1989 and July 2006 with FSRT. Most patients were treated for tumor progression after surgery. A median target dose of 52.2 grays (Gy) (range, 50.4-56 Gy) was applied in a median conventional fractionation of 5 x 1.8 Gy per week. Follow-up examinations included thorough clinical assessment as well as contrast-enhanced magnetic resonance imaging scans.
After a median follow-up of 98 months (range, 3-326 months), local control was 100% at both 5 years and 10 years. Overall survival rates at 5 years and 10 years were 97% and 89%, respectively. A complete response was observed in 4 patients and partial responses were noted in 25 patients. Eleven patients presented with stable disease during follow-up. Acute toxicity was mild in all patients. Long-term toxicity included enlargement of cysts requiring drainage 3 months after FSRT. No visual impairment, radionecrosis, or development of secondary malignancies were observed.
The long-term outcome of FSRT for craniopharyngiomas is excellent with regard to local control as well as treatment-related side effects.
评估了采用分次立体定向放射治疗(FSRT)的颅咽管瘤患者的长期预后。
1989年5月至2006年7月期间,共有40例颅咽管瘤患者接受了FSRT治疗。大多数患者因术后肿瘤进展而接受治疗。中位靶剂量为52.2格雷(Gy)(范围50.4 - 56 Gy),采用每周5次、每次1.8 Gy的中位常规分割方式。随访检查包括全面的临床评估以及增强磁共振成像扫描。
中位随访98个月(范围3 - 326个月)后,5年和10年时的局部控制率均为100%。5年和10年的总生存率分别为97%和89%。4例患者观察到完全缓解,25例患者观察到部分缓解。11例患者在随访期间病情稳定。所有患者的急性毒性均较轻。长期毒性包括FSRT后3个月囊肿增大需要引流。未观察到视力损害、放射性坏死或继发性恶性肿瘤的发生。
FSRT治疗颅咽管瘤的长期预后在局部控制以及治疗相关副作用方面都非常好。